Latest On Alexion Pharmaceuticals, Inc (ALXN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-07-26 12:08 EST | News | EMA advisory committee backs Alexion’s Ultomiris for blood disorder in children | N/A |  |
| 2021-07-22 18:39 EST | News | ICER finds Alexion's Soliris lacks cost-effectiveness for myasthenia gravis | N/A | |
| 2021-07-20 18:40 EST | News | U.K. competition regulator to investigate AstraZeneca's $39B acquisition of Alexion | N/A | |
| 2021-07-20 18:35 EST | News | AstraZeneca files with European Commission for planned Alexion acquisition | N/A | |
| 2021-07-20 18:31 EST | News | AstraZeneca appoints Aradhana Sarin as new finance chief | N/A | |
| 2021-07-20 18:30 EST | News | Alexion Ultomiris gains approval for rare blood disease in children | N/A | |
| 2021-07-20 18:17 EST | News | AstraZeneca’s acquisition of Alexion cleared in Europe | N/A | |
| 2021-07-20 18:08 EST | News | AstraZeneca's planned purchase of Alexion approved by U.K. competition regulator | N/A | |
| 2021-07-20 18:07 EST | News | Alexion Pharma last trading day next week, NASDAQ says | N/A | |
| 2021-07-20 18:07 EST | News | Alexion's autoimmune disorder treatment meets main goal in late-stage study | N/A | |
| 2021-07-20 18:07 EST | News | Moderna joining S&P 500, replacing Alexion | N/A | |
| 2021-05-06 06:56 EST | News | Alexion current acquisition price from AstraZeneca is too cheap, analyst says | N/A | |
| 2021-05-04 14:26 EST | News | AstraZeneca doesn't expect Alexion deal to see antitrust concerns in remaining reviews | N/A | |
| 2021-05-01 03:29 EST | News | Alexion Pharmaceuticals EPS beats by $0.38, beats on revenue | N/A | |
| 2021-05-01 03:29 EST | News | Alexion shares rise on Q1 earnings beat | N/A | |
| 2021-05-01 03:28 EST | News | Alexion Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation | N/A | |
| 2021-04-30 05:30 EST | News | Alexion Pharmaceuticals Q1 2021 Earnings Preview | N/A | |
| 2021-04-20 00:54 EST | News | Underperformance of healthcare sector masks its return to normalcy: WSJ | N/A | |
| 2021-04-16 08:52 EST | News | FTC clears AstraZeneca's acquisition of Alexion | N/A | |
| 2021-03-18 13:31 EST | News | Phase 3 data shows Apellis blood disorder drug besting Alexion's Soliris | N/A | |
| 2021-03-17 18:11 EST | News | FTC moves to hinder cross-border pharma mergers; CVS cut to neutral at Guggenheim and more in today’s analyst action | N/A | |
| 2021-03-17 12:04 EST | Analyst Rating | The Analyst Target Price has increased from $172.5 to $174.67. | Buy | |
| 2021-03-16 20:07 EST | Analyst Rating | The Analyst Target Price has decreased from $172.65 to $172.5. | Neutral | |
| 2021-03-16 18:57 EST | News | AstraZeneca's planned purchase of Alexion to be refiled with FTC | N/A | |
| 2021-03-16 18:57 EST | News | Watch Alexion as FTC says its considering new approach to pharmaceutical deals | N/A | |
| 2021-02-11 02:37 EST | News | PhaseBio shares spike 22% in afternoon trading | N/A | |
| 2021-02-09 03:05 EST | Analyst Rating | The Analyst Target Price has decreased from $172.88 to $172.65. | Neutral | |
| 2021-02-06 11:05 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-05 21:51 EST | News | Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-02-05 15:04 EST | Analyst Rating | The Analyst Target Price has decreased from $173.65 to $172.88. | Neutral | |
| 2021-02-05 15:04 EST | Earnings Estimate | An EPS average of $14.51 is estimated for the 2022 year. | Buy | |
| 2021-02-05 15:04 EST | Earnings Estimate | An EPS average of $3.29 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-04 09:09 EST | News | Alexion Pharmaceuticals EPS beats by $0.40, beats on revenue | N/A | |
| 2021-02-03 14:27 EST | News | Alexion Pharmaceuticals Q4 2020 Earnings Preview | N/A | |
| 2021-01-14 00:34 EST | News | Alexion to pause further enrolment in global late-stage COVID-19 study of ULTOMIRIS | N/A | |
| 2021-01-12 19:35 EST | News | Alexion Pharmaceuticals expects to exceed top end of revenue guidance | N/A | |
| 2021-01-12 19:35 EST | News | Alexion Pharmaceuticals (ALXN) Presents At J.P.Morgan Healthcare Conference - Slideshow | N/A | |
| 2021-01-12 19:35 EST | News | At JPM Alexion gives preview of what AstraZeneca is getting after shelling out $39B | N/A | |
| 2021-01-05 15:04 EST | Analyst Rating | The Analyst Target Price has increased from $170.71 to $173.65. | Buy | |
| 2020-12-17 03:05 EST | Analyst Rating | The Analyst Target Price has increased from $169.53 to $170.71. | Buy | |
| 2020-12-16 03:06 EST | Analyst Rating | The Analyst Target Price has increased from $167.06 to $169.53. | Buy | |
| 2020-12-15 07:52 EST | News | Apellis remains a top pick at Baird after AstraZeneca/Alexion deal | N/A | |
| 2020-12-15 03:07 EST | Analyst Rating | The Analyst Target Price has increased from $145.35 to $167.06. | Buy | |
| 2020-12-14 14:24 EST | News | AstraZeneca/Alexion deal earns mixed views on Wall Street | N/A | |
| 2020-12-14 14:23 EST | News | Astrazeneca/Alexion deal impacts IQVIA: BofA | N/A | |
| 2020-12-14 14:23 EST | News | Astrazeneca/Alexion merger could drive more deals: Piper Sandler | N/A | |
| 2020-12-13 22:05 EST | News | The Next Major Pharmaceutical Acquisition Is Here | N/A | |
| 2020-12-13 04:05 EST | News | AstraZeneca to acquire Alexion bulking up rare disease portfolio | N/A | |
| 2020-12-13 03:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-12 11:51 EST | News | AstraZeneca buying Alexion in $39B cash and stock deal | N/A | |
About Alexion Pharmaceuticals, Inc (ALXN):
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
General
- Name Alexion Pharmaceuticals, Inc
- Symbol ALXN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 3,837
- Last Split Factor2:1
- Last Split Date2011-05-23
- Fiscal Year EndDecember
- IPO Date1996-02-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.alexion.com
View More
Valuation
- Trailing PE 55.61
- Forward PE 12.02
- Price/Sales (Trailing 12 Mt.) 5.42
- Price/Book (Most Recent Quarter) 2.8
- Enterprise Value Revenue 5.33
- Enterprise Value EBITDA 32.28
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $13.08
- Next Year EPS Estimate $14.54
- Next Quarter EPS Estimate $3.10
- Profit Margin 10%
- Operating Margin 47%
- Return on Assets 10%
- Return on Equity 5%
- Revenue 6.07 billion
- Earnings Per Share $2.72
- Revenue Per Share $27.58
- Gross Profit 5.52 billion
- Quarterly Earnings Growth 15%
View More
Highlights
- Market Capitalization 33.26 billion
- EBITDA 3.19 billion
- PEG Ratio 2.09
- Analyst Target Price $174.67
- Book Value Per Share $53.08
View More
Share Statistics
- Shares Outstanding 219.85 million
- Shares Float 218.83 million
- % Held by Insiders 28%
- % Held by Institutions 93.36%
- Shares Short 8.45 million
- Shares Short Prior Month 7.9 million
- Short Ratio 3.29
- Short % of Float 4%
- Short % of Shares Outstanding 4%
View More
Technicals
- Beta 1.24
- 52 Week High $162.6
- 52 Week Low $77.23
- 50 Day Moving Average 153.68
- 200 Day Moving Average 135.74
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
ESG Rating
Alexion Pharmaceuticals, Inc (ALXN) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Alexion Pharmaceuticals, Inc (ALXN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-04 | $1.59 billion | $2.96 | $2.56 | 15.48% |
| 2020-09-30 | 2020-10-29 | $N/A | $3.24 | $2.60 | 24.58% |
| 2020-06-30 | 2020-07-30 | $N/A | $3.11 | $2.58 | 20.52% |
| 2020-03-31 | 2020-05-06 | $N/A | $3.22 | $2.71 | 18.67% |
| 2019-12-31 | 2020-01-30 | $1.38 billion | $2.71 | $2.61 | 3.86% |
| 2019-09-30 | 2019-10-23 | $1.26 billion | $2.79 | $2.48 | 12.69% |
| 2019-06-30 | 2019-07-24 | $1.2 billion | $2.64 | $2.34 | 12.9% |
| 2019-03-31 | 2019-04-25 | $1.14 billion | $2.39 | $2.21 | 8.3% |
| 2018-12-31 | 2019-02-04 | $1.13 billion | $2.14 | $1.84 | 16.39% |
| 2018-09-30 | 2018-10-24 | $1.03 billion | $2.02 | $1.74 | 16.09% |
| 2018-06-30 | 2018-07-26 | $1.05 billion | $2.07 | $1.72 | 20.48% |
| 2018-03-31 | 2018-04-26 | $930.9 million | $1.68 | $1.50 | 11.93% |
| 2017-12-31 | 2018-02-08 | $910.1 million | $1.48 | $1.27 | 16.11% |
| 2017-09-30 | 2017-10-26 | $859 million | $1.44 | $1.32 | 9.12% |
| 2017-06-30 | 2017-07-27 | $912 million | $1.56 | $1.26 | 24.28% |
| 2017-03-31 | 2017-04-27 | $870 million | $1.38 | $1.24 | 11.44% |
| 2016-12-31 | 2017-02-16 | $830.74 million | $1.26 | $1.25 | 0.95% |
| 2016-09-30 | 2016-10-27 | $799.11 million | $1.23 | $1.17 | 5.25% |
| 2016-06-30 | 2016-07-28 | $753.12 million | $1.13 | $1.17 | -3.76% |
| 2016-03-31 | 2016-04-28 | $701.04 million | $1.11 | $1.13 | -2.08% |
| 2015-12-31 | 2016-02-03 | $700.87 million | $1.13 | $1.10 | 2.82% |
| 2015-09-30 | 2015-10-29 | $666.64 million | $1.16 | $1.01 | 14.85% |
| 2015-06-30 | 2015-07-30 | $636.21 million | $1.44 | $1.38 | 4.35% |
| 2015-03-31 | 2015-04-23 | $600.33 million | $1.28 | $1.33 | -3.76% |
| 2014-12-31 | 2015-01-29 | $599.48 million | $1.30 | $1.29 | 0.78% |
| 2014-09-30 | 2014-10-23 | $555.15 million | $1.27 | $1.16 | 9.48% |
| 2014-06-30 | 2014-07-24 | $512.5 million | $1.12 | $1.07 | 4.67% |
| 2014-03-31 | 2014-04-24 | $566.62 million | $1.53 | $1.26 | 21.43% |
| 2013-12-31 | 2014-01-30 | $441.91 million | $0.87 | $0.83 | 4.82% |
| 2013-09-30 | 2013-10-24 | $400.41 million | $0.83 | $0.79 | 5.06% |
| 2013-06-30 | 2013-07-25 | $370.09 million | $0.73 | $0.68 | 7.35% |
| 2013-03-31 | 2013-04-25 | $338.94 million | $0.65 | $0.61 | 6.56% |
| 2012-12-31 | 2013-02-14 | $320.53 million | $0.60 | $0.53 | 13.21% |
| 2012-09-30 | 2012-10-24 | $294.14 million | $0.60 | $0.47 | 27.66% |
| 2012-06-30 | 2012-07-25 | $274.72 million | $0.47 | $0.37 | 27.03% |
| 2012-03-31 | 2012-04-24 | $244.73 million | $0.45 | $0.39 | 15.38% |
| 2011-12-31 | 2012-02-09 | $227.56 million | $0.41 | $0.34 | 20.59% |
| 2011-09-30 | 2011-10-20 | $204.05 million | $0.37 | $0.29 | 27.59% |
| 2011-06-30 | 2011-07-21 | $185.7 million | $0.29 | $0.27 | 7.41% |
| 2011-03-31 | 2011-04-21 | $166.13 million | $0.30 | $0.25 | 20% |
| 2010-12-31 | 2011-02-10 | $155.98 million | $0.26 | $0.25 | 4% |
| 2010-09-30 | 2010-10-21 | $141.57 million | $0.25 | $0.22 | 13.64% |
| 2010-06-30 | 2010-07-22 | $125.83 million | $0.20 | $0.19 | 5.26% |
| 2010-03-31 | 2010-04-22 | $117.58 million | $0.19 | $0.17 | 11.76% |
| 2009-12-31 | 2010-02-11 | $110.65 million | $0.16 | $0.12 | 33.33% |
| 2009-09-30 | 2009-10-22 | $102.63 million | $0.19 | $0.11 | 72.73% |
| 2009-06-30 | 2009-07-23 | $92.26 million | $0.13 | $0.08 | 62.5% |
| 2009-03-31 | 2009-04-23 | $81.27 million | $0.13 | $0.07 | 85.71% |
| 2008-12-31 | 2009-02-12 | $77.4 million | $0.09 | $0.04 | 125% |
| 2008-09-30 | 2008-10-23 | $76.5 million | $0.12 | $0.02 | 500% |
| 2008-06-30 | 2008-07-29 | $59.56 million | $0.02 | -$0.03 | 166.67% |
| 2008-03-31 | 2008-04-30 | $45.64 million | -$0.03 | -$0.11 | 72.73% |
| 2007-12-31 | 2008-02-14 | $33.86 million | -$0.08 | -$0.12 | 33.33% |
| 2007-09-30 | 2007-10-25 | $22.11 million | -$0.14 | -$0.18 | 22.22% |
| 2007-06-30 | 2007-07-25 | $9.76 million | -$0.19 | -$0.26 | 26.92% |
| 2007-03-31 | 2007-05-01 | $6.32 million | -$0.23 | -$0.27 | 14.81% |
| 2006-12-31 | 2007-02-15 | $188000 | -$0.30 | -$0.29 | -3.45% |
| 2006-09-30 | 2006-11-01 | $263000 | -$0.25 | -$0.27 | 7.41% |
| 2006-06-30 | 2006-08-08 | $339000 | -$0.26 | -$0.22 | -18.18% |
| 2006-03-31 | 2006-04-27 | $768000 | -$0.22 | -$0.25 | 12% |
| 2005-09-30 | 2005-10-05 | -$0.29 | -$0.28 | -3.57% | |
| 2005-03-31 | 2005-06-03 | $151000 | -$0.29 | -$0.26 | -11.54% |
| 2004-12-31 | 2005-03-04 | $563000 | -$0.22 | -$0.24 | 8.33% |
| 2004-09-30 | 2004-12-03 | $147000 | -$0.17 | -$0.25 | 32% |
| 2004-06-30 | 2004-09-24 | $4.15 million | -$0.22 | -$0.29 | 24.14% |
| 2004-03-31 | 2004-06-03 | $168000 | -$0.17 | -$0.27 | 37.04% |
| 2003-12-31 | 2004-03-05 | $147000 | -$0.21 | -$0.25 | 16% |
| 2003-09-30 | 2003-10-03 | $147000 | -$0.29 | -$0.32 | 9.38% |
| 2003-03-31 | 2003-06-06 | $167000 | -$0.27 | -$0.30 | 10% |
| 2002-12-31 | 2003-03-07 | $220000 | -$0.29 | -$0.31 | 6.45% |
| 2002-09-30 | 2002-10-04 | $323000 | -$0.29 | -$0.32 | 9.38% |
| 2002-03-31 | 2002-06-07 | $539000 | -$0.23 | -$0.31 | 25.81% |
| 2001-12-31 | 2002-03-08 | $3.38 million | -$0.15 | -$0.22 | 31.82% |
| 2001-09-30 | 2001-10-05 | $1.86 million | -$0.09 | -$0.11 | 18.18% |
| 2001-03-31 | 2001-06-07 | $1.96 million | -$0.08 | -$0.10 | 20% |
| 2000-12-31 | 2001-03-08 | $3.17 million | -$0.05 | -$0.16 | 68.75% |
| 2000-09-30 | 2000-10-05 | $3.4 million | -$0.08 | -$0.11 | 27.27% |
| 2000-06-30 | 2000-07-31 | $3.99 million | -$0.08 | ||
| 2000-03-31 | 2000-06-08 | $4.48 million | -$0.10 | -$0.07 | -42.86% |
| 1999-12-31 | 2000-02-28 | $6.68 million | -$0.06 | -$0.07 | 14.29% |
| 1999-09-30 | 1999-10-08 | -$0.09 | -$0.08 | -12.5% | |
| 1999-03-31 | 1999-06-10 | $0.14 | $0.13 | 7.69% | |
| 1998-12-31 | 1999-03-11 | -$0.11 | -$0.07 | -57.14% | |
| 1998-09-30 | 1998-10-08 | -$0.08 | -$0.08 | 0% | |
| 1998-03-31 | 1998-05-28 | -$0.07 | -$0.08 | 12.5% | |
| 1997-12-31 | 1998-03-12 | -$0.08 | -$0.08 | 0% | |
| 1997-09-30 | 1997-12-09 | $0.03 | $0.02 | 50% | |
| 1997-03-31 | 1997-06-16 | -$0.06 | -$0.08 | 25% | |
| 1996-12-31 | 1997-03-17 | -$0.04 | -$0.07 | 42.86% | |
| 1996-09-30 | 1996-10-30 | -$0.07 | -$0.08 | 12.5% | |
| 1996-03-31 | 1996-06-18 | -$0.04 | -$0.07 | 42.86% |
Alexion Pharmaceuticals, Inc (ALXN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 295 million | N/A | N/A | N/A | 269.6 million |
| Income Before Tax | 590.6 million | N/A | N/A | N/A | 602 million |
| Selling General Administrative | 444.4 million | N/A | N/A | N/A | 381 million |
| Gross Profit | 1.44 billion | N/A | N/A | N/A | 1.27 billion |
| Ebit | 693.4 million | N/A | N/A | N/A | 545.5 million |
| Operating Income | 647 million | N/A | N/A | N/A | 545.5 million |
| Income Tax Expense | 54.8 million | 88.8 million | -284 million | 106 million | -287 million |
| Total Revenue | 1.59 billion | N/A | N/A | N/A | 1.38 billion |
| Cost of Revenue | 152.2 million | N/A | N/A | N/A | 114.3 million |
| Total Other Income Expense Net | -28.7 million | N/A | N/A | N/A | 56.5 million |
| Net Income From Continuing Operations | 535.8 million | N/A | N/A | N/A | 889 million |
| Net Income Applicable to Common Shares | 535.8 million | 578.1 million | -1.07 billion | 557.6 million | 889 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | 41.7 million |
| Change to Liabilities | 112.2 million | -20.3 million | -68.2 million | N/A | 183.5 million |
| Total Cash Flow from Investing Activities | -1.27 billion | 14.5 million | -766 million | N/A | -8.5 million |
| Net Borrowings | -32.6 million | -32.7 million | -32.6 million | N/A | -32.7 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | -365.9 million |
| Change to Operating Activities | -37.5 million | 18.1 million | -72.9 million | N/A | 84.6 million |
| Change in Cash | N/A | N/A | N/A | N/A | 218.3 million |
| Total Cash from Operating Activities | 822.8 million | 790 million | 549.6 million | N/A | 599.5 million |
| Depreciation | N/A | N/A | N/A | N/A | 92.5 million |
| Other Cash Flow from Investing Activities | -300000 | -600000 | -3.6 million | N/A | -300000 |
| Change to Inventory | N/A | N/A | N/A | N/A | -81.9 million |
| Change to Account Receivables | N/A | N/A | N/A | N/A | -2.7 million |
| Other Cash Flow from Financing Activities | -10.5 million | -16.2 million | -1.3 million | N/A | -1.3 million |
| Change to Net Income | 135.9 million | 1.84 billion | 127.4 million | N/A | -144.1 million |
| Capital Expenditures | N/A | N/A | N/A | N/A | 41.9 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 6.45 billion | N/A | N/A | N/A | 6.27 billion |
| Total Stockholder Equity | 11.65 billion | N/A | N/A | N/A | 11.27 billion |
| Other Current Liabilities | 279 million | 79.2 million | N/A | N/A | 100.9 million |
| Total Assets | 18.1 billion | N/A | N/A | N/A | 17.54 billion |
| Common Stock | 11.65 billion | N/A | 10.49 billion | N/A | 11.27 billion |
| Other Current Assets | N/A | 72.1 million | N/A | N/A | N/A |
| Retained Earnings | N/A | 4.71 billion | N/A | 5.2 billion | N/A |
| Other Liabilities | 2.23 billion | 2.36 billion | 2.61 billion | 2.6 billion | 2.54 billion |
| Other Assets | 2.71 billion | 2.89 billion | 2.79 billion | 2.66 billion | 2.72 billion |
| Cash | 2.96 billion | N/A | N/A | N/A | 2.69 billion |
| Total Current Liabilities | 1.62 billion | 1.33 billion | N/A | N/A | 1.19 billion |
| Other Stockholder Equity | N/A | -119.2 million | N/A | -101.5 million | N/A |
| Property, Plant & Equipment | 1.46 billion | 1.43 billion | 1.41 billion | 1.36 billion | 1.37 billion |
| Total Current Assets | 5.83 billion | 5.07 billion | N/A | N/A | 5.08 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 3.55 billion | 2.92 billion | 3.36 billion | 2.49 billion | 2.89 billion |
| Short Term Investments | 34.9 million | N/A | N/A | N/A | 64 million |
| Long Term Debt | 2.42 billion | N/A | N/A | N/A | 2.38 billion |
| Inventory | 775.7 million | 729 million | N/A | N/A | 627.6 million |
| Accounts Payable | 1.2 billion | 89.2 million | N/A | N/A | 966.7 million |
Alexion Pharmaceuticals, Inc (ALXN) Chart:
Alexion Pharmaceuticals, Inc (ALXN) News:
Below you will find a list of latest news for Alexion Pharmaceuticals, Inc (ALXN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Alexion Pharmaceuticals, Inc (ALXN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Alexion Pharmaceuticals, Inc (ALXN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000110465920080237/0001104659-20-080237-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000008025519002417/0000080255-19-002417-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000008025520001036/0000080255-20-001036-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000009375119000044/0000093751-19-000044-index.htm |
| 2020-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000009375120000376/0000093751-20-000376-index.htm |
| 2019-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000021545719003322/0000215457-19-003322-index.htm |
| 2018-11-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000031506618002481/0000315066-18-002481-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000031506619000851/0000315066-19-000851-index.htm |
| 2020-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000031506620000024/0000315066-20-000024-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000083423720004782/0000834237-20-004782-index.htm |
| 2020-07-23 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089924320020313/0000899243-20-020313-index.htm |
| 2020-07-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089924320020565/0000899243-20-020565-index.htm |
| 2018-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986618000107/0000899866-18-000107-index.htm |
| 2018-07-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986618000114/0000899866-18-000114-index.htm |
| 2018-07-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986618000116/0000899866-18-000116-index.htm |
| 2018-07-26 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/899866/000089986618000121/0000899866-18-000121-index.htm |
| 2018-08-14 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/899866/000089986618000123/0000899866-18-000123-index.htm |
| 2018-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986618000126/0000899866-18-000126-index.htm |
| 2018-10-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986618000128/0000899866-18-000128-index.htm |
| 2018-10-24 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/899866/000089986618000131/0000899866-18-000131-index.htm |
| 2018-11-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986618000133/0000899866-18-000133-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986618000135/0000899866-18-000135-index.htm |
| 2018-12-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986618000137/0000899866-18-000137-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000005/0000899866-19-000005-index.htm |
| 2019-02-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986619000007/0000899866-19-000007-index.htm |
| 2019-02-06 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/899866/000089986619000010/0000899866-19-000010-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000011/0000899866-19-000011-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000012/0000899866-19-000012-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000013/0000899866-19-000013-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000016/0000899866-19-000016-index.htm |
| 2019-02-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000018/0000899866-19-000018-index.htm |
| 2019-02-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000021/0000899866-19-000021-index.htm |
| 2019-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000022/0000899866-19-000022-index.htm |
| 2019-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000024/0000899866-19-000024-index.htm |
| 2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000025/0000899866-19-000025-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000035/0000899866-19-000035-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000036/0000899866-19-000036-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000037/0000899866-19-000037-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000038/0000899866-19-000038-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000039/0000899866-19-000039-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000040/0000899866-19-000040-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000041/0000899866-19-000041-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000042/0000899866-19-000042-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000043/0000899866-19-000043-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000044/0000899866-19-000044-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000045/0000899866-19-000045-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000046/0000899866-19-000046-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000047/0000899866-19-000047-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000048/0000899866-19-000048-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000049/0000899866-19-000049-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000050/0000899866-19-000050-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000051/0000899866-19-000051-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000052/0000899866-19-000052-index.htm |
| 2019-03-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/899866/000089986619000054/0000899866-19-000054-index.htm |
| 2019-03-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/899866/000089986619000056/0000899866-19-000056-index.htm |
| 2019-04-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986619000059/0000899866-19-000059-index.htm |
| 2019-04-25 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/899866/000089986619000061/0000899866-19-000061-index.htm |
| 2019-05-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986619000064/0000899866-19-000064-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000065/0000899866-19-000065-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000066/0000899866-19-000066-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000067/0000899866-19-000067-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000068/0000899866-19-000068-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000070/0000899866-19-000070-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000071/0000899866-19-000071-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000072/0000899866-19-000072-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000073/0000899866-19-000073-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000074/0000899866-19-000074-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000075/0000899866-19-000075-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000076/0000899866-19-000076-index.htm |
| 2019-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000077/0000899866-19-000077-index.htm |
| 2019-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000078/0000899866-19-000078-index.htm |
| 2019-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000079/0000899866-19-000079-index.htm |
| 2019-07-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000080/0000899866-19-000080-index.htm |
| 2019-07-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986619000085/0000899866-19-000085-index.htm |
| 2019-07-24 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/899866/000089986619000087/0000899866-19-000087-index.htm |
| 2019-09-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986619000089/0000899866-19-000089-index.htm |
| 2019-09-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986619000091/0000899866-19-000091-index.htm |
| 2019-10-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986619000093/0000899866-19-000093-index.htm |
| 2019-10-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986619000097/0000899866-19-000097-index.htm |
| 2019-10-23 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/899866/000089986619000099/0000899866-19-000099-index.htm |
| 2019-11-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000101/0000899866-19-000101-index.htm |
| 2019-12-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000102/0000899866-19-000102-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000103/0000899866-19-000103-index.htm |
| 2019-12-04 | 3/A | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000104/0000899866-19-000104-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986619000105/0000899866-19-000105-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000002/0000899866-20-000002-index.htm |
| 2020-01-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000005/0000899866-20-000005-index.htm |
| 2020-01-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000009/0000899866-20-000009-index.htm |
| 2020-02-04 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/899866/000089986620000012/0000899866-20-000012-index.htm |
| 2020-02-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000013/0000899866-20-000013-index.htm |
| 2020-02-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000014/0000899866-20-000014-index.htm |
| 2020-02-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000015/0000899866-20-000015-index.htm |
| 2020-02-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000016/0000899866-20-000016-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000017/0000899866-20-000017-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000018/0000899866-20-000018-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000019/0000899866-20-000019-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000020/0000899866-20-000020-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000021/0000899866-20-000021-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000022/0000899866-20-000022-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000023/0000899866-20-000023-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000024/0000899866-20-000024-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000025/0000899866-20-000025-index.htm |
| 2020-03-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000026/0000899866-20-000026-index.htm |
| 2020-03-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/899866/000089986620000032/0000899866-20-000032-index.htm |
| 2020-03-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/899866/000089986620000034/0000899866-20-000034-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000035/0000899866-20-000035-index.htm |
| 2020-04-09 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/899866/000089986620000037/0000899866-20-000037-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000040/0000899866-20-000040-index.htm |
| 2020-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/899866/000089986620000042/0000899866-20-000042-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000043/0000899866-20-000043-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000044/0000899866-20-000044-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000045/0000899866-20-000045-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000046/0000899866-20-000046-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000047/0000899866-20-000047-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000048/0000899866-20-000048-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000049/0000899866-20-000049-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000050/0000899866-20-000050-index.htm |
| 2020-05-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000053/0000899866-20-000053-index.htm |
| 2020-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000056/0000899866-20-000056-index.htm |
| 2020-06-03 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000061/0000899866-20-000061-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000062/0000899866-20-000062-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000063/0000899866-20-000063-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000064/0000899866-20-000064-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000089986620000065/0000899866-20-000065-index.htm |
| 2020-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000072/0000899866-20-000072-index.htm |
| 2020-07-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/899866/000089986620000074/0000899866-20-000074-index.htm |
| 2020-08-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000076/0000899866-20-000076-index.htm |
| 2020-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000081/0000899866-20-000081-index.htm |
| 2020-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000089986620000086/0000899866-20-000086-index.htm |
| 2020-10-29 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/899866/000089986620000088/0000899866-20-000088-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000093247119004674/0000932471-19-004674-index.htm |
| 2020-05-27 | SC TO-T | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/899866/000104746920003213/0001047469-20-003213-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/899866/000110465920018504/0001104659-20-018504-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000110465920056508/0001104659-20-056508-index.htm |
| 2020-05-05 | SC TO-C | Written communication relating to an issuer or third party | https://www.sec.gov/Archives/edgar/data/899866/000110465920056509/0001104659-20-056509-index.htm |
| 2020-05-05 | SC TO-C | Written communication relating to an issuer or third party | https://www.sec.gov/Archives/edgar/data/899866/000110465920056972/0001104659-20-056972-index.htm |
| 2020-05-06 | SC TO-C | Written communication relating to an issuer or third party | https://www.sec.gov/Archives/edgar/data/899866/000110465920057102/0001104659-20-057102-index.htm |
| 2020-05-07 | SC TO-C | Written communication relating to an issuer or third party | https://www.sec.gov/Archives/edgar/data/899866/000110465920058134/0001104659-20-058134-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000110465920058178/0001104659-20-058178-index.htm |
| 2020-05-07 | SC TO-C | Written communication relating to an issuer or third party | https://www.sec.gov/Archives/edgar/data/899866/000110465920058180/0001104659-20-058180-index.htm |
| 2020-06-01 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/899866/000110465920068398/0001104659-20-068398-index.htm |
| 2020-06-05 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/899866/000110465920070485/0001104659-20-070485-index.htm |
| 2020-06-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/899866/000110465920070492/0001104659-20-070492-index.htm |
| 2020-06-15 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/899866/000110465920073188/0001104659-20-073188-index.htm |
| 2020-06-24 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/899866/000110465920076477/0001104659-20-076477-index.htm |
| 2020-06-25 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/899866/000110465920076668/0001104659-20-076668-index.htm |
| 2020-07-02 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/899866/000110465920080055/0001104659-20-080055-index.htm |
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000110465920080237/0001104659-20-080237-index.htm |
| 2020-07-31 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/899866/000110465920088466/0001104659-20-088466-index.htm |
| 2019-10-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/899866/000119312519268091/0001193125-19-268091-index.htm |
| 2019-10-16 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/899866/000119312519268098/0001193125-19-268098-index.htm |
| 2019-05-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000163859919000533/0001638599-19-000533-index.htm |
| 2019-05-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2020-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/899866/000163859920000500/0001638599-20-000500-index.htm |
| 2018-12-17 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/899866/999999999718009582/9999999997-18-009582-index.htm |
| 2020-04-06 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/899866/999999999720001339/9999999997-20-001339-index.htm |
Alexion Pharmaceuticals, Inc (ALXN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alexion Pharmaceuticals, Inc (ALXN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 28%Institutional Ownership: 9336%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-05-14 | Francois Nader | Director | Buy | 3,468.00 | 10,345.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000045/0000899866-20-000045-index.htm | ||
| 2020-05-14 | PAUL A FRIEDMAN | Director | Buy | 3,468.00 | 10,345.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000044/0000899866-20-000044-index.htm | ||
| 2020-05-14 | Judith A Reinsdorf | Director | Buy | 3,468.00 | 10,920.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000047/0000899866-20-000047-index.htm | ||
| 2020-05-14 | Deborah Dunsire | Director | Buy | 3,468.00 | 11,193.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000043/0000899866-20-000043-index.htm | ||
| 2020-05-14 | Francois Nader | Director | Buy | 941.00 | 11,286.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000045/0000899866-20-000045-index.htm | ||
| 2020-05-14 | Judith A Reinsdorf | Director | Buy | 595.00 | 11,515.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000047/0000899866-20-000047-index.htm | ||
| 2019-05-15 | David R Brennan | Director | Buy | 1,908.00 | 11,641.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000073/0000899866-19-000073-index.htm | ||
| 2020-05-14 | Deborah Dunsire | Director | Buy | 941.00 | 12,134.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000043/0000899866-20-000043-index.htm | ||
| 2020-05-14 | John T Mollen | Director | Buy | 3,468.00 | 12,701.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000048/0000899866-20-000048-index.htm | ||
| 2018-12-31 | LUDWIG HANTSON | CEO | Sell | 3,244.00 | 95.85 | 310,937.40 | 150,696.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000005/0000899866-19-000005-index.htm |
| 2020-05-14 | David R Brennan | Director | Buy | 3,468.00 | 15,109.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000050/0000899866-20-000050-index.htm | ||
| 2019-02-28 | Ellen Chiniara | EVP & General Counsel | Buy | 8,250.00 | 15,961.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000046/0000899866-19-000046-index.htm | ||
| 2019-02-28 | LUDWIG HANTSON | CEO | Buy | 37,198.00 | 170,836.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000052/0000899866-19-000052-index.htm | ||
| 2020-05-14 | David R Brennan | Director | Buy | 2,428.00 | 17,537.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000050/0000899866-20-000050-index.htm | ||
| 2020-02-28 | Tanisha Carino | EVP & CCAO | Buy | 9,520.00 | 18,297.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000022/0000899866-20-000022-index.htm | ||
| 2020-02-28 | LUDWIG HANTSON | CEO | Buy | 44,201.00 | 202,266.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000025/0000899866-20-000025-index.htm | ||
| 2019-05-15 | Andreas Rummelt | Director | Buy | 2,726.00 | 22,146.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000066/0000899866-19-000066-index.htm | ||
| 2019-12-15 | Ellen Chiniara | EVP & Chief Legal Officer | Buy | 54.00 | 93.86 | 5,068.44 | 24,952.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000026/0000899866-20-000026-index.htm |
| 2020-02-28 | Daniel Bazarko | SVP, Controller, CAO | Buy | 3,927.00 | 25,210.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000024/0000899866-20-000024-index.htm | ||
| 2020-05-14 | Andreas Rummelt | Director | Buy | 3,468.00 | 25,614.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000049/0000899866-20-000049-index.htm | ||
| 2020-02-28 | Ellen Chiniara | EVP & Chief Legal Officer | Buy | 10,200.00 | 26,161.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000026/0000899866-20-000026-index.htm | ||
| 2020-06-08 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sell | 1,433.00 | 115.00 | 164,795.00 | 28,218.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000065/0000899866-20-000065-index.htm |
| 2018-11-28 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sell | 2,605.00 | 118.13 | 307,728.65 | 29,304.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986618000135/0000899866-18-000135-index.htm |
| 2019-07-01 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sell | 4,500.00 | 132.78 | 597,510.00 | 29,627.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000079/0000899866-19-000079-index.htm |
| 2020-06-08 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Sell | 5,420.00 | 114.61 | 621,186.20 | 29,651.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000065/0000899866-20-000065-index.htm |
| 2019-06-21 | ARADHANA SARIN | Chief Strategy & Business Off | Sell | 578.00 | 132.00 | 76,296.00 | 30,201.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000078/0000899866-19-000078-index.htm |
| 2019-02-28 | ARADHANA SARIN | Chief Strategy & Business Off | Buy | 8,250.00 | 30,779.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000051/0000899866-19-000051-index.htm | ||
| 2018-12-15 | JOHN J ORLOFF | EVP, Research & Development | Buy | 34.00 | 93.01 | 3,162.34 | 31,149.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000041/0000899866-19-000041-index.htm |
| 2019-05-15 | CHRISTOPHER J COUGHLIN | Director | Buy | 2,726.00 | 31,233.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000067/0000899866-19-000067-index.htm | ||
| 2019-05-15 | CHRISTOPHER J COUGHLIN | Director | Buy | 2,181.00 | 33,414.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000067/0000899866-19-000067-index.htm | ||
| 2019-02-28 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Buy | 8,250.00 | 35,531.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000050/0000899866-19-000050-index.htm | ||
| 2020-02-28 | ARADHANA SARIN | EVP, CFO | Buy | 10,880.00 | 35,640.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000020/0000899866-20-000020-index.htm | ||
| 2020-05-14 | CHRISTOPHER J COUGHLIN | Director | Buy | 3,468.00 | 36,882.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000046/0000899866-20-000046-index.htm | ||
| 2019-02-28 | ANNE-MARIE LAW | EVP, Chief Experience Officer | Buy | 8,839.00 | 37,655.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000044/0000899866-19-000044-index.htm | ||
| 2020-02-28 | Indrani Lall Franchini | EVP, Chief Compliance Officer | Buy | 9,520.00 | 37,741.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000018/0000899866-20-000018-index.htm | ||
| 2020-05-14 | CHRISTOPHER J COUGHLIN | Director | Buy | 2,774.00 | 39,656.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000046/0000899866-20-000046-index.htm | ||
| 2019-02-28 | JOHN J ORLOFF | EVP, Research & Development | Buy | 9,428.00 | 40,577.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000048/0000899866-19-000048-index.htm | ||
| 2019-02-28 | Brian Goff | EVP & Chief Commercial Officer | Buy | 9,428.00 | 43,419.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000049/0000899866-19-000049-index.htm | ||
| 2020-02-28 | ANNE-MARIE LAW | EVP, Chief Experience Officer | Buy | 10,200.00 | 45,292.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000021/0000899866-20-000021-index.htm | ||
| 2019-12-15 | JOHN J ORLOFF | EVP, Research & Development | Buy | 38.00 | 93.86 | 3,566.68 | 47,313.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000023/0000899866-20-000023-index.htm |
| 2020-02-28 | JOHN J ORLOFF | EVP, Research & Development | Buy | 10,880.00 | 48,671.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000023/0000899866-20-000023-index.htm | ||
| 2019-02-14 | Daniel Bazarko | SVP, Controller, CAO | Sell | 2,000.00 | 126.00 | 252,000.00 | 5,020.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000022/0000899866-19-000022-index.htm |
| 2020-02-28 | Brian Goff | EVP & Chief Commercial Officer | Buy | 10,880.00 | 51,062.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986620000019/0000899866-20-000019-index.htm | ||
| 2019-05-15 | Francois Nader | Director | Buy | 2,726.00 | 6,877.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000072/0000899866-19-000072-index.htm | ||
| 2019-05-15 | PAUL A FRIEDMAN | Director | Buy | 2,726.00 | 6,877.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000068/0000899866-19-000068-index.htm | ||
| 2019-05-15 | Deborah Dunsire | Director | Buy | 2,726.00 | 6,985.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000070/0000899866-19-000070-index.htm | ||
| 2019-05-15 | Judith A Reinsdorf | Director | Buy | 2,726.00 | 6,985.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000065/0000899866-19-000065-index.htm | ||
| 2019-05-30 | BROS. ADVISORS LP BAKER | Director | Sell | 22,720.00 | 120.77 | 2,743,928.48 | 7,382,978.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-30 | BROS. ADVISORS LP BAKER | Director | Sell | 13,213.00 | 122.31 | 1,616,054.28 | 7,405,698.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 32,228.00 | 75.66 | 2,438,422.04 | 7,415,206.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-30 | BROS. ADVISORS LP BAKER | Director | Sell | 15,355.00 | 120.12 | 1,844,459.49 | 7,418,911.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 8,309.00 | 77.89 | 647,202.97 | 7,423,515.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 7,612.00 | 77.94 | 593,260.25 | 7,431,127.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-29 | BROS. ADVISORS LP BAKER | Director | Sell | 35,796.00 | 122.37 | 4,380,431.69 | 7,434,266.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-15 | Judith A Reinsdorf | Director | Buy | 467.00 | 7,452.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000065/0000899866-19-000065-index.htm | ||
| 2019-05-29 | BROS. ADVISORS LP BAKER | Director | Sell | 30,766.00 | 123.06 | 3,786,036.27 | 7,470,062.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-29 | BROS. ADVISORS LP BAKER | Director | Sell | 39,732.00 | 121.37 | 4,822,189.40 | 7,500,828.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-28 | BROS. ADVISORS LP BAKER | Director | Sell | 71,819.00 | 127.06 | 9,125,257.50 | 7,540,560.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-02-28 | Daniel Bazarko | SVP, Controller, CAO | Buy | 3,403.00 | 7,543.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000047/0000899866-19-000047-index.htm | ||
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 133,042.00 | 79.14 | 10,529,170.05 | 7,564,169.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-28 | BROS. ADVISORS LP BAKER | Director | Sell | 22,886.00 | 125.05 | 2,861,901.17 | 7,612,379.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 62,129.00 | 79.77 | 4,955,719.69 | 7,626,298.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-28 | BROS. ADVISORS LP BAKER | Director | Sell | 15,541.00 | 126.25 | 1,962,085.44 | 7,635,265.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-15 | BROS. ADVISORS LP BAKER | Director | Buy | 2,726.00 | 7,650,806.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000533/0001638599-19-000533-index.htm | ||
| 2020-03-17 | BROS. ADVISORS LP BAKER | Director | Buy | 27,866.00 | 76.10 | 2,120,479.99 | 7,654,164.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-17 | BROS. ADVISORS LP BAKER | Director | Buy | 65,505.00 | 76.67 | 5,022,445.21 | 7,719,669.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-17 | BROS. ADVISORS LP BAKER | Director | Buy | 565.00 | 78.66 | 44,442.90 | 7,720,234.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 4,191.00 | 79.16 | 331,760.40 | 7,724,425.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-15 | Deborah Dunsire | Director | Buy | 740.00 | 7,725.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000070/0000899866-19-000070-index.htm | ||
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 2,888.00 | 79.29 | 228,979.99 | 7,727,313.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 26,022.00 | 79.72 | 2,074,361.95 | 7,753,335.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 10,285.00 | 79.87 | 821,429.01 | 7,763,620.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 3,298.00 | 80.91 | 266,845.47 | 7,766,918.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 12,815.00 | 81.09 | 1,039,177.32 | 7,779,733.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 4,203.00 | 81.47 | 342,438.16 | 7,783,936.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 25,640.00 | 81.79 | 2,097,003.30 | 7,809,576.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 15,928.00 | 82.13 | 1,308,149.12 | 7,825,504.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 1,321.00 | 82.92 | 109,536.53 | 7,826,825.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 14,731.00 | 83.14 | 1,224,797.21 | 7,841,556.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-05-14 | BROS. ADVISORS LP BAKER | Director | Buy | 3,468.00 | 7,845,024.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000500/0001638599-20-000500-index.htm | ||
| 2020-05-14 | BROS. ADVISORS LP BAKER | Director | Buy | 1,189.00 | 7,846,213.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000500/0001638599-20-000500-index.htm | ||
| 2019-11-29 | Tanisha Carino | EVP & CCAO | Buy | 8,777.00 | 8,777.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000102/0000899866-19-000102-index.htm | ||
| 2019-05-15 | John T Mollen | Director | Buy | 2,726.00 | 9,233.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000071/0000899866-19-000071-index.htm | ||
| 2018-07-10 | Paul J Clancy | EVP, Chief Financial Officer | Sell | 5,241.00 | 131.11 | 687,147.51 | 93,309.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986618000114/0000899866-18-000114-index.htm |
| 2019-05-30 | BROS. ADVISORS LP BAKER | Director | Sell | 2,729.00 | 120.77 | 329,585.42 | 952,874.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-30 | BROS. ADVISORS LP BAKER | Director | Sell | 1,587.00 | 122.31 | 194,102.64 | 955,603.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 2,911.00 | 75.66 | 220,250.92 | 955,785.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 750.00 | 77.89 | 58,418.85 | 956,535.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-02-28 | Paul J Clancy | EVP, Chief Financial Officer | Buy | 9,428.00 | 95,677.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000045/0000899866-19-000045-index.htm | ||
| 2019-05-30 | BROS. ADVISORS LP BAKER | Director | Sell | 1,845.00 | 120.12 | 221,623.43 | 957,190.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 688.00 | 77.94 | 53,621.00 | 957,223.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-29 | BROS. ADVISORS LP BAKER | Director | Sell | 4,300.00 | 122.37 | 526,200.03 | 959,035.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-29 | BROS. ADVISORS LP BAKER | Director | Sell | 3,696.00 | 123.06 | 454,826.43 | 963,335.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-29 | BROS. ADVISORS LP BAKER | Director | Sell | 4,772.00 | 121.37 | 579,167.62 | 967,031.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 12,017.00 | 79.14 | 951,045.81 | 969,240.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-28 | BROS. ADVISORS LP BAKER | Director | Sell | 8,627.00 | 127.06 | 1,096,138.86 | 971,803.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-15 | David R Brennan | Director | Buy | 2,726.00 | 9,733.00 | https://www.sec.gov/Archives/edgar/data/899866/000089986619000073/0000899866-19-000073-index.htm | ||
| 2020-03-16 | BROS. ADVISORS LP BAKER | Director | Buy | 5,612.00 | 79.77 | 447,641.18 | 974,852.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-17 | BROS. ADVISORS LP BAKER | Director | Buy | 2,517.00 | 76.10 | 191,532.63 | 977,369.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-28 | BROS. ADVISORS LP BAKER | Director | Sell | 2,749.00 | 125.05 | 343,763.27 | 980,430.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2019-05-28 | BROS. ADVISORS LP BAKER | Director | Sell | 1,867.00 | 126.25 | 235,712.86 | 983,179.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000561/0001638599-19-000561-index.htm |
| 2020-03-17 | BROS. ADVISORS LP BAKER | Director | Buy | 5,917.00 | 76.67 | 453,672.37 | 983,286.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-17 | BROS. ADVISORS LP BAKER | Director | Buy | 51.00 | 78.66 | 4,011.66 | 983,337.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 379.00 | 79.16 | 30,001.72 | 983,716.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 261.00 | 79.29 | 20,693.83 | 983,977.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2019-05-15 | BROS. ADVISORS LP BAKER | Director | Buy | 2,726.00 | 985,046.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859919000533/0001638599-19-000533-index.htm | ||
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 2,351.00 | 79.72 | 187,411.61 | 986,328.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 929.00 | 79.87 | 74,196.16 | 987,257.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 298.00 | 80.91 | 24,111.57 | 987,555.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000321/0001638599-20-000321-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 1,158.00 | 81.09 | 93,903.03 | 988,713.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 380.00 | 81.47 | 30,960.39 | 989,093.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 2,314.00 | 81.79 | 189,253.73 | 991,407.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 1,439.00 | 82.13 | 118,183.49 | 992,846.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 119.00 | 82.92 | 9,867.41 | 992,965.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-03-18 | BROS. ADVISORS LP BAKER | Director | Buy | 1,331.00 | 83.14 | 110,664.93 | 994,296.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000322/0001638599-20-000322-index.htm |
| 2020-05-14 | BROS. ADVISORS LP BAKER | Director | Buy | 3,468.00 | 997,764.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000500/0001638599-20-000500-index.htm | ||
| 2020-05-14 | BROS. ADVISORS LP BAKER | Director | Buy | 1,189.00 | 998,953.00 | https://www.sec.gov/Archives/edgar/data/899866/000163859920000500/0001638599-20-000500-index.htm |